Pfizer ends new cholesterol drug trial

Pfizer Inc. said it halted all clinical trials and development of torcetrapib, which was part of the company's efforts to help boost good cholesterol.

December 4, 2006 08:31
1 minute read.


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


MarketWatch: In-depth global business coverage Pfizer Inc. said it halted all clinical trials and development of torcetrapib, which was part of the company's efforts to help boost good cholesterol. In a statement, the company said the independent Data-Safety Monitoring Board urged the company to end the clinical trial "because of an imbalance of mortality and cardiovascular events." The New York drugmaker said it stopped the trial in the interest of patient safety and was notifying the US Food and Drug Administration and other regulators that it was ending the study. Pfizer also asked clinical investigators to inform patients to stop taking the drug immediately. Pfizer said it has ended its program to develop torcetrapib but that the end of the torcetrapib study has no impact on the safety and efficacy of its Lipitor cholesterol drug. In an October news release, Pfizer had said that torcetrapib with Lipitor significantly increased good, or HDL, cholesterol by 55% to 60% and lowered bad, or LDL, cholesterol by 10% to 15% relative to patients who were taking only Lipitor. Joseph Feczko, Pfizer's chief medical officer, said then that the data supported "our fundamental premise: this innovative medicine really can 'do both' and manage total cholesterol successfully." At the same time, the company emphasized that the data at that point were not yet complete and still needed further analysis. In its latest statement, Pfizer's chief executive, Jeffrey B. Kindler, said the recommendation from the monitoring board was "surprising and disappointing." Nonetheless, the executive affirmed Pfizer's financial estimates for 2006. MarketWatch: In-depth global business coverage

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection


Cookie Settings